05.28.26 -- Why Contamination Control By Design Should Matter To Your CDMO

Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major late‑stage risks.

See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.

Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

Smart analytical decisions made early can prevent costly issues later. Real-world examples show how right-sized analytics enable smoother scale-up and fewer late-stage surprises.

This collaboration demonstrates how a partnership-driven approach, combined with technical expertise, can deliver scalable and reliable solutions that support successful global commercialization.

Leverage a hybridoma discovery and humanization platform to develop high-affinity, cross-reactive monoclonal antibodies against Type I transmembrane protein targets.

A transposon‑enabled cell line development strategy streamlines upstream optimization, shortening timelines while improving consistency, yield, and quality across recombinant protein modalities.

Advanced cell line strategies improve stability and chain pairing while accelerating production, helping developers overcome scalability, productivity, and timeline challenges.

Bioprocess changes require robust comparability strategies that combine risk assessment, advanced analytics, and regulatory expectations to keep biologics safe, effective, and compliant.

Successful tech transfer depends on solid documentation, early teamwork, clear expectations, proactive risk planning, and experienced partners to keep execution smooth and projects moving on schedule.

Early planning for scale-up and biologics license application activities can maximize your chances of success by allowing sufficient time to develop launch options and prevent costly delays and setbacks.

Outlined here are the benefits of PFS and how they relate to the delivery of drugs, how SARS-CoV-2 could be fueling an explosive increase in demand, and how partnering with a flexible CDMO is key.